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The emergence and spread of drug resistant pathogens and our
inability to develop new antimicrobials to combat resistance (pheno-
typic and genetic) has motivated scientists to consider non-traditional
targets where human homologs clearly exist. Cellular bioenergetics is an
area showing promise for the development of new antimicrobials, but
the success of this area will only emerge by understanding the role of
these energetic processes (e.g. respiration and oxidative phosphoryla-
tion) under conditions that prevail in host tissues. In this session, wewill
examine the recent developments in the ﬁeld suggesting cellular
energetics as a target space for the development of new antimicrobials.
doi:10.1016/j.bbabio.2014.05.032
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Energy metabolism has emerged as a new target-pathway for
development of new anti-tubercular drugs [1]. We investigated a
selective ATP synthase inhibitor, bedaquiline (TMC207)[2-4] and
its target, mycobacterial ATP synthase [5]. In this poster we present
insight into the chemical biology of this new drug/target system,
elucidating the bacterial metabolic response upon bedaquiline treat-
ment. BDQ treatment of mycobacteria triggered upregulation of
pathways involved in ATP production, including enzymes of the
glycolytic pathway, the pyruvate dehydrogenase complex and the
tricarboxylic acid cycle, as well as ATP synthase and the cytochrome bd
oxidase [6]. In contrast, major biosynthetic pathways were downregu-
lated upon BDQ treatment, including ribosomal protein synthesis, DNA
biosynthesis and synthesis of mycolic acids, a key component of the
mycobacterial cell envelope [6]. These changes in the mycobacterial
proteome reﬂect a general strategy employed by mycobacteria for
preserving ATP pools, minimizing consumption of cellular ATP and
utilizing alternative ATP-generating pathways. [1] D. Bald, A. Koul.
Advances and strategies in discovery of new antibacterials for combating
metabolically resting bacteria. Drug Discov. Today 18 (2013) 250-255.
[2] K. Andries, P. Verhasselt, J. Guillemont, et al. A diarylquinoline drug
active on the ATP synthase of Mycobacterium tuberculosis. Science 307
(2005) 223-227. [3] A. Koul, N. Dendouga, K. Vergauwen et al.
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat.
Chem. Biol. 3 (2007) 323-324. [4] A.C. Haagsma, I. Podasca, A. et al.
Probing the interaction of the diarylquinoline TMC207 with its target
mycobacterial ATP synthase. PLoS One 6 (2011) e23575 [5] A.C.
Haagsma, N.N. Driessen, M.M. Hahn et al. ATP synthase in slow- and
fast-growing mycobacteria is active in ATP synthesis and blocked in ATP
hydrolysis direction. FEMSMicrobiol. Lett. 313 (2010) 68-74. [6] A. Koul,
L. Vrancks, N. Dhar et al. Delayed bactericidal response ofMycobacterium
tuberculosis to bedaquiline involves remodeling of bacterialmetabolism.
Nat. Commun. 5 (2014) 3369.
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With the increasing occurrence of drug resistance in diseases
including tuberculosis (TB) new drug targets, new lead compounds,
and new antimicrobial strategies are all of interest. Recently TMC207/
Bedaquiline, a compound that inhibits ATP synthesis in mycobacteria,
was approved for use in patients withmultidrug-resistant or extensively
drug resistant-TB suggesting that oxidative phosphorylation is a
vulnerable drug target in mycobacteria. This view is supported by
studies from our laboratory and others that suggest menaquinone
synthesis (required for electron transport inmycobacteria) is also a valid
drug target. Recent data indicates that saturation of a single isoprene unit
in the menaquinone of Mycobacterium tuberculosis represents a novel
virulence factor for this pathogen. Rv0561c, annotated as a possible
oxidoreductase, in the Mycobacterium tuberculosis H37Rv genome and
MSMEG1132 in Mycobacterium smegmatis are shown to encode
enzymes that increase the mass of menaquinone by two AMU. Mass
spectral analysis unambiguously demonstrated that these enzymes did
not reduce the aromatic ring moieties, but increased the mass of the
isoprenyl side chains by reducing one double bond. Thus, this previously
undescribed reductase catalyzes the ﬁnal step in the synthesis of the
predominant form of menaquinone found in mycobacteria and, presum-
ably, other Gram-positive bacteria that synthesize partially saturated
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menaquinone. Deletion mutants have reduced oxygen consumption
rates and electron transport efﬁciency, although membrane integrity,
cellular ATP levels and rates of ATP synthesis are unaltered as are
bacterial growth rates. However, in vitro infection studies using J774A.1
cells and theM. tuberculosis Rv0561c deletionmutant demonstrated that
the mutant is unable to survive in macrophage-like cells. Thus, Rv0561c
represents a novel, contextually essential enzyme that is a potential
drug target inM. tuberculosis. Funded by NIH/NIAID grant # AI049151.
doi:10.1016/j.bbabio.2014.05.034
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In addition to haem copper oxidases, all higher plants, some algae,
yeasts, molds, metazoans, and pathogenic microorganisms such as
Trypanosoma brucei contain an additional terminal oxidase, the
cyanide-insensitive alternative oxidase (AOX). AOX is a diiron carbox-
ylate protein that catalyzes the four-electron reduction of dioxygen to
water by ubiquinol. In T. brucei, a parasite that causes human African
sleeping sickness, AOX plays a critical role in the survival of the parasite
in its bloodstream form. Because AOX is absent from mammals, this
protein represents a unique and promising therapeutic target. This talk
will discuss recent crystal structures of the trypanosomal alternative
oxidase obtained in the absence and presence of speciﬁc inhibitors. All
structures reveal that the oxidase is a homodimer with the non-haem
diiron carboxylate active site buried within a four-helix bundle. CAVER
protein analysis reveals that there are two hydrophobic cavities per
monomer. One cavity, which is perpendicular to themembrane surface,
binds both inhibitors and substratewithin 4 Å of the active sitewhereas
the second cavity, which is parallel to the membrane surface and also
links with the active-site, acts as an oxygen/H2O channel. We suggest
that detailed knowledge of the nature of the inhibitor/substrate cavity
will lead to a greater rational design of anti-trypanosomal drugs.
doi:10.1016/j.bbabio.2014.05.035
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Most studies on cancer metabolism have been carried out in cells
cultured with high glucose (25 mM; hyperglycemia). However, the
glucose concentrations range from 5 mM in well blood-irrigated
areas to 0.25–2.5 mM in areas within solid tumors that are away
from blood vessels. These low glucose levels may induce changes in
the cancer cell behavior. Indeed, it is well documented that culturing
with low glucose promotes substantial variations in the mRNA levels
of a multitude of genes. However, no evidences have been so far
provided about the impact that such transcriptional remodeling
has on the protein contents and activities of enzymes/transporters
and, perhaps more importantly, whether these changes signiﬁcantly
modify pathway ﬂuxes and cellular functions.
In the present study, it was analyzed that the effect of hypoglycemia
on the contents of glycolytic and mitochondrial proteins, activities of
enzymes/transporters and ﬂuxes of glycolysis and oxidative phosphor-
ylation (OxPhos) in HeLa andMCF-7 tumor cells. One day hypoglycemia
(2.5 mM initial glucose) induced increased protein levels of glucose
transporters (GLUT) 1 and 3 (2–3 fold) and hexokinase I (HK; 2.3-fold),
compared to hyperglycemia. Remarkably, these increases were not
accompanied by increases in the total cellular activities (i.e. Vmax) of
GLUT and HK; instead, increased afﬁnity of these activities for glucose
surged, which may explain the 2-fold increased glycolytic ﬂux under
hypoglycemia. Therefore, a change towards greater catalytically ef-
ﬁcient isoforms of two of the main controlling steps sufﬁced to induce
increased glycolytic ﬂux.
Hypoglycemia also induced a decrease in the pyruvate dehydroge-
nase content and increase in the respiratory complex I, with no variation
in those of isocitrate dehydrogenase and 2-oxoglutarate dehydrogenase.
The activities ofmalate dehydrogenase, fumarase and citrate synthase, as
well as the OxPhos ﬂux (i.e., rate of O2 consumption sensitive to
oligomycin) and the electrical membrane potential, were not modiﬁed
by hypoglycemia. Hence, the contribution to the ATP supply by glycolysis
increased from 27–35% under hyperglycemia to 44–70% under hypogly-
cemia, depending on the cancer cell type, and noting that OxPhos
contribution was still signiﬁcant. Therefore, the results indicated that, to
effectively diminish the accelerated cancer cell growth, the two energy
metabolism pathways should be targeted simultaneously.
doi:10.1016/j.bbabio.2014.05.036
S12.O2
Functional and structural characterization of a Staphyloccocus
aureus ﬂavohemoglobin
Myriam MoussaouiI
Laboratoire Chimie Physique, France
E-mail address: moussaoui.myriam@gmail.com
Flavohemoglobins (ﬂavoHbs) play a key role in bacterial resistance
to nitrosative stress and NO signaling modulation. Typically, ﬂavoHbs
contains three domains: an N-terminal globin domain which harbors
a single heme type b and a C-terminal ferredoxin reductase-like FAD-
and NAD-binding module. In this presentation, we cloned, expressed
and characterized the ﬂavoHb from the opportunistic pathogen,
Staphylococcus aureus. The high amino acid sequence homology with
Saccharomyces cerevisaewas used to build a model structure by homol-
ogymodeling showing structural similaritieswith those of other known
ﬂavoHbs. Interestingly this high sequence homology did not correlate
with the enzymatic and kinetic properties which are much similar to
those of Escherichia coli. In vitro and aerobically, the enzyme accepts
cytochrome c and oxygen as substrate. Based on this feature, we
showed that in Staphylococcus aureus and Ralstonia eutropha ﬂavoHbs
the preferences for cytochrome c and dioxygen depending on the
presence of NO dioxygenase inhibitors are different and this is deter-
mined by the inhibitor chemical composition. To make progress in
understanding the catalyticmechanism of ﬂavoHbswe investigated the
enzyme properties, the effect of azole antibiotics and the structure-
function relationship in comparison to the well-known ﬂavoHbs from
the non-pathogenic bacteria. The mutation of key residues situated in
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